ResearcherDokkyo Medical UniversityActive in the last 2 years
Shozo Mori
Matched on ORCID iD 0000-0002-6289-0905; OpenAlex author ID A5100619621. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2019: 1 paper · 2020: none · 2021: 4 papers · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS. First author DOI 10.3390/cancers16050910↗
- Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-021-04267-5↗
- Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001826↗
- Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.14925↗
- Clinical Predictors of Unresectable Disease at Laparotomy in Patients With Pancreatic Ductal Adenocarcinoma Planning to Undergo Surgical Resection. Co-author DOI 10.21873/anticanres.15335↗
- Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.21873/invivo.11700↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Taku Aoki · 6 shared papers, 2019–2024 · strength 0.96
- Paper Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS. DOI 10.3390/cancers16050910↗
- Paper Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal aden… DOI 10.1007/s00280-021-04267-5↗
- Paper Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic D… DOI 10.1097/mpa.0000000000001826↗
- Keiichi Kubota · 6 shared papers, 2019–2024 · strength 0.96
- Paper Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS. DOI 10.3390/cancers16050910↗
- Paper Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal aden… DOI 10.1007/s00280-021-04267-5↗
- Paper Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic D… DOI 10.1097/mpa.0000000000001826↗
- Takayuki Shimizu · 5 shared papers, 2019–2021 · strength 0.60
- Paper Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal aden… DOI 10.1007/s00280-021-04267-5↗
- Paper Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic D… DOI 10.1097/mpa.0000000000001826↗
- Paper Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients Wit… DOI 10.21873/anticanres.14925↗
- Takatsugu Matsumoto · 4 shared papers, 2021 · strength 0.51
- Paper Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal aden… DOI 10.1007/s00280-021-04267-5↗
- Paper Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic D… DOI 10.1097/mpa.0000000000001826↗
- Paper Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients Wit… DOI 10.21873/anticanres.14925↗
- Takashi Suzuki · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.